These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 30332965

  • 21. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
    Thibault B, Jean-Claude B.
    J Ovarian Res; 2017 Apr 26; 10(1):31. PubMed ID: 28446239
    [Abstract] [Full Text] [Related]

  • 22. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.
    Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM.
    Clin Cancer Res; 2009 Nov 15; 15(22):6852-61. PubMed ID: 19861436
    [Abstract] [Full Text] [Related]

  • 23. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.
    Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R.
    Oncogene; 2001 May 03; 20(20):2499-513. PubMed ID: 11420660
    [Abstract] [Full Text] [Related]

  • 24. MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells.
    Liu L, Gaboriaud N, Vougogianopoulou K, Tian Y, Wu J, Wen W, Skaltsounis L, Jove R.
    Cancer Biol Ther; 2014 Feb 03; 15(2):178-84. PubMed ID: 24100507
    [Abstract] [Full Text] [Related]

  • 25. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.
    van Oosterwijk JG, van Ruler MA, Briaire-de Bruijn IH, Herpers B, Gelderblom H, van de Water B, Bovée JV.
    Br J Cancer; 2013 Sep 03; 109(5):1214-22. PubMed ID: 23922104
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
    Barrio S, Gallardo M, Arenas A, Ayala R, Rapado I, Rueda D, Jiménez-Ubieto A, Albizua E, Burgaleta C, Gilsanz F, Martinez-Lopez J.
    Br J Haematol; 2013 Jun 03; 161(5):667-676. PubMed ID: 23560534
    [Abstract] [Full Text] [Related]

  • 27. Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.
    Viktorsson K, Shah CH, Juntti T, Hååg P, Zielinska-Chomej K, Sierakowiak A, Holmsten K, Tu J, Spira J, Kanter L, Lewensohn R, Ullén A.
    Mol Oncol; 2016 May 03; 10(5):719-34. PubMed ID: 26827254
    [Abstract] [Full Text] [Related]

  • 28. A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells.
    Xiao H, Bid HK, Jou D, Wu X, Yu W, Li C, Houghton PJ, Lin J.
    J Biol Chem; 2015 Feb 06; 290(6):3418-29. PubMed ID: 25313399
    [Abstract] [Full Text] [Related]

  • 29. Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
    Jia J, Starodub A, Cushman I, Liu Y, Marshall DJ, Hurwitz HI, Nixon AB.
    Anticancer Drugs; 2013 Mar 06; 24(3):237-50. PubMed ID: 23275294
    [Abstract] [Full Text] [Related]

  • 30. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
    Inge LJ, Fowler AJ, Paquette KM, Richer AL, Tran N, Bremner RM.
    J Thorac Cardiovasc Surg; 2013 Feb 06; 145(2):531-8. PubMed ID: 23142123
    [Abstract] [Full Text] [Related]

  • 31. Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.
    Stanley A, Ashrafi GH, Seddon AM, Modjtahedi H.
    Sci Rep; 2017 Jun 21; 7(1):3964. PubMed ID: 28638122
    [Abstract] [Full Text] [Related]

  • 32. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM, Mueller K, Gartner E, Boerner J.
    J Surg Res; 2013 Nov 21; 185(1):231-9. PubMed ID: 23899511
    [Abstract] [Full Text] [Related]

  • 33. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
    Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE.
    Oncogene; 2010 Jun 03; 29(22):3208-16. PubMed ID: 20383201
    [Abstract] [Full Text] [Related]

  • 34. Lusianthridin targeting of lung cancer stem cells via Src-STAT3 suppression.
    Bhummaphan N, Petpiroon N, Prakhongcheep O, Sritularak B, Chanvorachote P.
    Phytomedicine; 2019 Sep 03; 62():152932. PubMed ID: 31100681
    [Abstract] [Full Text] [Related]

  • 35. Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.
    Zhao W, Zhang T, Qu B, Wu X, Zhu X, Meng F, Gu Y, Shu Y, Shen Y, Sun Y, Xu Q.
    Anticancer Drugs; 2011 Jan 03; 22(1):79-88. PubMed ID: 20881478
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
    Wang L, Guo B, Wang R, Jiang Y, Qin S, Liang S, Zhao Y, Guo W, Li K, Fan X.
    Clin Sci (Lond); 2012 Jan 03; 122(1):13-24. PubMed ID: 21751967
    [Abstract] [Full Text] [Related]

  • 37. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
    Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR, Hong KL, Ginther C, Winterhoff B, Gao G, Brugge J, Slamon DJ.
    Br J Cancer; 2009 Nov 17; 101(10):1699-708. PubMed ID: 19861960
    [Abstract] [Full Text] [Related]

  • 38. Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
    Chang AY, Wang M.
    BMC Cancer; 2013 May 30; 13():267. PubMed ID: 23721490
    [Abstract] [Full Text] [Related]

  • 39. Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.
    Petersen W, Liu J, Yuan L, Zhang H, Schneiderjan M, Cho YJ, MacDonald TJ.
    Cancer Lett; 2014 Nov 01; 354(1):68-76. PubMed ID: 25107642
    [Abstract] [Full Text] [Related]

  • 40. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways.
    Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, Yu H.
    Mol Cancer Res; 2010 Jan 01; 8(1):35-45. PubMed ID: 20053726
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.